Physician

Derek Weldon Holland, M.D.

According to 2025 Medicare claims, Derek Holland, M.D. (NPI: 1487603817) practices hematology/oncology in the Chattanooga, TN-GA market, with the plurality of this provider's patient population coming from Hamilton, TN. This provider's primary affiliated billing organization is TENNESSEE ONCOLOGY PLLC (NPI: 1811955917; TIN: 621647259) and primary practice location at 37404-2744. Holland is affiliated with the Main Street Rural Health Cedar ACO LLC (ACO ID: A5502), participating under the MSSP model.

Holland's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 680 traditional Medicare patients, billed 134,736 HCPCS/CPT codes, and received $3,176,181 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,840 prescription claims across 402 beneficiaries totaling $6,764,573 in drug costs, led by Pomalyst (Pomalidomide). DME data shows 47 claims. Open Payments data shows 5 records totaling $135. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,996,088 to $3,176,181. Similarly, Part D prescription costs have risen steadily, from $1,817,014 to $6,764,573. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $8,730 to $3,478.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	754	152,066	$1,996,088
2016	777	191,940	$2,215,528
2017	767	173,505	$2,753,643
2018	811	203,132	$2,551,743
2019	761	244,625	$2,286,084
2020	698	187,539	$2,404,011
2021	700	187,946	$2,667,273
2022	698	207,462	$2,576,735
2023	718	230,884	$3,678,248
2024	680	134,736	$3,176,181

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	314	2,492	$1,817,014
2016	312	2,576	$2,833,760
2017	306	2,281	$2,922,227
2018	346	2,462	$3,545,630
2019	353	2,411	$4,335,925
2020	337	2,386	$4,214,068
2021	315	2,002	$3,133,011
2022	345	1,857	$3,952,656
2023	378	2,560	$5,465,353
2024	402	2,840	$6,764,573

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	238	$34,227
2016	27	176	$55,188
2017	22	142	$18,678
2018	11	152	$16,058
2019	N/R	102	$7,737
2020	N/R	47	$4,058
2021	N/R	127	$8,015
2022	N/R	91	$4,931
2023	N/R	98	$10,721
2024	N/R	47	$1,082

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	275	680	$86
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	280	469	$59
80053	Blood test, comprehensive group of blood chemicals	422	1,763	$10
36415	Insertion of needle into vein for collection of blood sample	435	1,859	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	468	2,238	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	58	1,603	$1,233,716
Calquence	Acalabrutinib Maleate	65	1,950	$784,601
Revlimid	Lenalidomide	49	1,251	$712,200
Ibrance	Palbociclib	29	812	$459,035
Imbruvica	Ibrutinib	24	672	$396,235

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	17	$427
K0003	Lightweight wheelchair	Y	N/R	12	$335
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	18	$320

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	5	$135	Aveo Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Derek Weldon Holland, M.D.?

Tedicare shows public-source Medicare data for Derek Weldon Holland, M.D. (NPI 1487603817), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Derek Weldon Holland, M.D. have ACO affiliation data?

Derek Weldon Holland, M.D. is shown with ACO affiliation data for Main Street Rural Health Cedar ACO LLC (MSSP, ACO ID A5502).

What billing organization is linked to Derek Weldon Holland, M.D.?

Derek Weldon Holland, M.D. is linked to TENNESSEE ONCOLOGY PLLC (billing NPI 1811955917) in the available physician profile data.

Does Derek Weldon Holland, M.D. have Open Payments data?

Derek Weldon Holland, M.D. has 5 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.